相关实验视频
Updated: Jul 10, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.3K
LINC01140 通过向miR-200b-3p来阻碍乳腺癌的发展,从而降低DMD的调节
Gongling Peng1, Jiaqi Yan1, Pengfei Shi1
1Department of Thyroid and Breast, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cell transplantation
|November 27, 2023
概括
长非编码RNA LINC01140通过通过miR-200b-3p向下调节营养不良蛋白 (DMD) 抑制乳腺癌 (BC). 这种机制抑制了瘤的生长,扩散和转移,为BC.提供了潜在的治疗点.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (lncRNAs) 在癌症发展中发挥着重要作用.
- 乳腺癌 (BC) 的进展受到各种分子机制的影响,包括lncRNA活性.
研究的目的:
- 研究lncRNA LINC01140在乳腺癌中的作用和机制.
- 为了阐明在BC中LINC01140,miR-200b-3p和素 (DMD) 之间的相互作用.
主要方法:
- 定量实时聚合酶链反应 (qRT-PCR) 用于基因表达分析.
- 西方涂抹用于蛋白质水平量的量化.
- 在体外测试 (CCK-8,殖民地形成,划痕,transwell) 和体内裸体小鼠模型用于功能研究.
- 路西法酶记者测定和RNA免疫沉用于相互作用验证.
主要成果:
- 在BC中,LINC01140和素 (DMD) 的调节下降,而miR-200b-3p的调节上升.
- LINC01140直接针对miR-200b-3p,导致DMD表达的减少.
- 过度表达LINC01140抑制了BC细胞的增殖,迁移,入侵和瘤生长,同时诱导了亡.
- miR-200b-3p促进了BC瘤性,而DMD过度表达限制了它.
结论:
- 在乳腺癌中,LINC01140通过miR-200b-3p-DMD轴作为瘤抑制剂起作用.
- 该LINC01140-miR-200b-3p-DMD网络代表了BC治疗的潜在治疗目标.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K

